M Lloret1,2,3, L García-Cabrera4, A Hernandez4, N Santana4, L López-Molina4, P C Lara5,6,7. 1. Department of Radiation Oncology, Dr. Negrin Hospital, Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain. mllosae@gobiernodecanarias.org. 2. Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain. mllosae@gobiernodecanarias.org. 3. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain. mllosae@gobiernodecanarias.org. 4. Department of Radiation Oncology, Dr. Negrin Hospital, Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain. 5. Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain. 6. Universidad Fernando Pessoa Canarias, Las Palmas, Spain. 7. Hospital Universitario San Roque, Las Palmas, Spain.
Abstract
BACKGROUND: Hyperthermia (HT) is used to increase the temperature of the tumor-sensitizing cells to the effects of radiation/chemotherapy. We aimed to assess the feasibility, tolerability and safety of hyperthermia treatment in a Radiation Oncology Department. METHODS: Between June 2015 and June 2017, 106 patients and a total of 159 tumor lesions were included in a prospective study (EudraCT 2018-001089-40) of HT concomitant with radiotherapy (RT). Systemic treatment was accepted. HT was given twice a week, 60 min per session, during RT treatment by a regional capacitive device (HY-DEEP 600WM system) at 13.56 MHz radiofrequency. RESULTS: Most lesions (138 cases, 86.8%) received all HT sessions planned. Thirteen lesions (12 patients) withdrew treatment due to grade ≥3 QMHT toxicity. All these 12 patients completed the prescribed radiotherapy and/or systemic treatment. CONCLUSIONS: Regional hyperthermia is a feasible and safe technique to be used in combination with radiotherapy and systemic treatment.
BACKGROUND:Hyperthermia (HT) is used to increase the temperature of the tumor-sensitizing cells to the effects of radiation/chemotherapy. We aimed to assess the feasibility, tolerability and safety of hyperthermia treatment in a Radiation Oncology Department. METHODS: Between June 2015 and June 2017, 106 patients and a total of 159 tumor lesions were included in a prospective study (EudraCT 2018-001089-40) of HT concomitant with radiotherapy (RT). Systemic treatment was accepted. HT was given twice a week, 60 min per session, during RT treatment by a regional capacitive device (HY-DEEP 600WM system) at 13.56 MHz radiofrequency. RESULTS: Most lesions (138 cases, 86.8%) received all HT sessions planned. Thirteen lesions (12 patients) withdrew treatment due to grade ≥3 QMHT toxicity. All these 12 patients completed the prescribed radiotherapy and/or systemic treatment. CONCLUSIONS: Regional hyperthermia is a feasible and safe technique to be used in combination with radiotherapy and systemic treatment.
Authors: Gregor Bruggmoser; Stefan Bauchowitz; Richard Canters; Hans Crezee; Michael Ehmann; Johanna Gellermann; Ulf Lamprecht; Nicoletta Lomax; Marc Benjamin Messmer; Oliver Ott; Sultan Abdel-Rahman; Rolf Sauer; Manfred Schmidt; Andreas Thomsen; Rüdiger Wessalowski; Gerard van Rhoon Journal: Strahlenther Onkol Date: 2011-09-19 Impact factor: 3.621
Authors: J J Lagendijk; G C Van Rhoon; S N Hornsleth; P Wust; A C De Leeuw; C J Schneider; J D Van Dijk; J Van Der Zee; R Van Heek-Romanowski; S A Rahman; C Gromoll Journal: Int J Hyperthermia Date: 1998 Mar-Apr Impact factor: 3.914
Authors: G Bruggmoser; S Bauchowitz; R Canters; H Crezee; M Ehmann; J Gellermann; U Lamprecht; N Lomax; M B Messmer; O Ott; S Abdel-Rahman; M Schmidt; R Sauer; A Thomsen; R Wessalowski; G van Rhoon Journal: Strahlenther Onkol Date: 2012-09 Impact factor: 3.621
Authors: P Wust; J Gellermann; C Harder; W Tilly; B Rau; S Dinges; P Schlag; V Budach; R Felix Journal: Int J Radiat Oncol Biol Phys Date: 1998-07-15 Impact factor: 7.038